Study of a new low molecular weight heparin (LU 47311) administered to healthy volunteers.
A newly developed low molecular weight heparin (LU 47311) was given to 6 healthy volunteers (males, mean age: 30.5 years, range: 20-39 years). They obtained a single dose of 40 and 60 anti FXaU per kg body weight, respectively, by subcutaneous administration. The anti FXa elimination half-life was close to 3 hours. The APTT showed slight response following high dose. No significant influence on fibrinolysis as measured by t-PA and PAI assays was noticed. There was no clear evidence of enhancement of platelet function when detected by Born's method and platelet factor 4 and beta-thromboglobulin assays. However, a moderate but significant increase of thromboxane B2 was noticed in the group obtaining an elevated dose of LMW heparin. Serum levels of triglycerides and cholesterol remained unaltered. The aminotransferases, electrolytes, renal function parameters and cell counts of the peripheral blood were not influenced by LMW heparin.
Pindur
G
G
Department of Clinical Haemostaseology and Transfusions Medicine, University Saarland, Saar, Homburg, BRD.
Köhler
M
M
Wenzel
E
E
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D010976:Platelet Count / Q000187:drug effects; D010978:Platelet Factor 4 / Q000378:metabolism; D013929:Thromboxane B2 / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D010978:Platelet Factor 4; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010959:Tissue Plasminogen Activator